Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
📈 **POSITIVE** • Low confidence analysis (55%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (77%) **Content type:** Clinical